Non Hodgkin's Lymphoma
Cyberfamily
The latest in Lymphoma treatments and research
The ASH education book series is a yearly overview of the treatment, management and diagnosis of many haematologic diseases.
These articles are long, very in-depth and come with links to the charts and figures showing the data from the studies they are presenting. They are aimed at doctors and researchers so the language and knowledge level is somewhat technical. Nevertheless they are also an excellent resource for us patients if you don't mind wading through them. They give you a very excellent idea of what is the current thinking on various topics.
Here is a list of titles in the current issue.
The first topic is about DLBC. The title and link are below. I think all people with DLBC will find something of interest in this article. (More to come)
Diffuse Large B-Cell Lymphoma: Risk Stratification and Management of Relapsed Disease
Peripheral T-cell lymphomas of all types. This will interest anyone with T-cell lymphomas.
Aggressive Peripheral T-Cell Lymphomas (Specified and Unspecified Types)
EBV has been implicated in several types of lymphoma, primarily Burkitt's lymphoma. Here is an article on this subject.
Biology and Treatment of Epstein-Barr Virus-Associated Non-Hodgkin Lymphomas
The title says it all for this one.
Clinical Presentation and Management of Marginal Zone Lymphomas
A topic of interest to all those with indolent lymphoma. Transformation to a more aggressive form is something that most patients with indolent lymphoma are concerned about.
Biology and Management of Histologic Transformation of Indolent Lymphoma
A must read for those with follicular lymphoma.
Targeting CD20 in Follicular NHL: Novel Anti-CD20 Therapies, Antibody Engineering, and the Use of Radioimmunoconjugates
Is Rituxan entirely without risks? Read this article for more information on this topic.
Unique Toxicities and Resistance Mechanisms Associated with Monoclonal Antibody Therapy
Another very hot topic.
Umbilical Cord Blood Transplantation: A New Alternative Option
Just what is the best schedule for Monoclonal Antibody therapy? Read on to find out.
Multimodality Therapies and Optimal Schedule of Antibodies: Rituximab in Lymphoma as an Example
Commonly referred to as mini-transplants, reduced intensity transplants are making transplant available to many more people who were previously not eligible.
Reduced-Intensity Conditioning Regimens for Hematologic Malignancies: What Have We Learned over the Last 10 Years?
An excellent article by Randy Gascoyne one of the worlds most prominent haematopathologists, from the British Columbia Cancer Agency.
Hematopathology Approaches to Diagnosis and Prognosis of Indolent B-Cell Lymphomas
© 2006 NHL Cyberfamily All Rights Reserved.
Web design by Long2 Consulting